A low level of the cholinergic neurotransmitter, acetylcholine, correlates with cognitive impairments in AD cases; hence, inhibition of the acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), the acetylcholine degrading enzymes, might delay AD onset. Here, BCHE is linked to Cognitive impairment.